Story

Tenax Therapeutics Stock Plummets Over 84% After Heart Drug Fails Pivotal Phase 3 Trial

ENTHMSVIIDZHZH-TWJAKOHI
Aug 10, 20262 min read
Tenax Therapeutics Stock Plummets Over 84% After Heart Drug Fails Pivotal Phase 3 Trial
Text size
Background

Tenax Therapeutics (TENX) stock plummeted 84.2% in pre-open trading after the company announced its pivotal Phase 3 LEVEL trial for TNX-103, an oral form of levosimendan, failed to achieve its primary goal. The sharp decline reflects a near-total collapse in investor confidence in the drug's immediate path to regulatory approval.

Trial Misses Key Endpoints

The study evaluated the drug in patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF), a condition with no currently approved therapies. The trial's primary endpoint was a statistically significant improvement in the 6-minute walk distance compared to a placebo.

According to the company's disclosure, the trial failed to meet this goal, showing a least-squares mean difference of just 3.5 meters with a p-value of 0.63, indicating the result was not statistically significant. The study also missed its key secondary endpoint, which measured improvement in the Kansas City Cardiomyopathy Questionnaire total symptom score, dealing a second blow to the drug's prospects.

Sample IUX Markets – In-articleAd

High Expectations Dashed

The trial failure is particularly damaging given the significant bullish sentiment that had built up among analysts ahead of the results. In recent weeks, firms including Chardan, Guggenheim, and Piper Sandler had initiated coverage or raised price targets, with some targets reaching as high as $50, based on expectations of a positive outcome. The company itself had recently hired a Chief Commercial Officer to prepare for a potential launch, a move that now appears premature.

With the failure of this binary catalyst, investor focus will now shift to the company's future strategy. Tenax noted that prespecified subgroup analyses suggested a beneficial effect in patients with a higher disease burden and that the drug was generally safe and well-tolerated. The company's cash runway of $118 million, expected to last through mid-2028, will be critical as it evaluates its next steps, including the ongoing global Phase 3 LEVEL-2 trial.

Read next

More on Stocks
Back to latest news

LATEST